pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
MYCO-003 · news · pharmadog
← back to MYCO-003
News mentioning MYCO-003
59
stories
3d
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
biospace
3d
Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
fiercebiotech
6d
HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
biospace
7d
FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
biospace
7d
ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
fiercebiotech
8d
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
biopharma dive
10d
Update: Compass submits psilocybin depression drug for approval after stock wobbles
biospace
10d
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
fiercebiotech
15d
STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill
stat
15d
STAT+: CVS Health to split, reversing years of deal-making to combine pharmacies and insurance
stat
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug
stat
16d
STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
stat
16d
STAT+: Who will get the first psychedelic approved?
stat
16d
STAT+: What do the midterms mean for health care?
stat
16d
‘Three-parent IVF’ was supposed to prevent mitochondrial disease. Studies are raising doubts
stat
17d
Washington state resident dies from bird flu following exposure to infected cattle
stat
17d
STAT+: The health care affordability midterms, and billing urgent care as ER
stat
17d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
Oct 15, 26
Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
stat
Oct 5, 26
Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
fiercebiotech
Sep 21, 26
How J&J paved the way for Compass’ coming psychedelic drug launch
biopharma dive
Sep 16, 26
Deep dive: Psychedelics back on FDA’s doorstep
biospace
Sep 15, 26
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
biospace
Sep 14, 26
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
fiercebiotech
Sep 14, 26
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
Sep 9, 26
Compass posts positive psilocybin data; Solstice makes $225M debut
endpoints
Sep 3, 26
Psilocybin proves promising in neuropathic pain mouse study
fiercebiotech
Aug 20, 26
STAT+: How a Trump loyalist got the FDA nomination
stat
Aug 20, 26
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
← prev
page 1 of 2
next →